Using Blood and Saliva mRNA to Detect Breast Cancer
This patent describes a method using specific messenger RNA (mRNA) levels in blood or saliva to help detect breast cancer or determine its prognosis.
Original patent title: “Biomarkers for the diagnosis of breast cancer”
This patent describes a method using specific messenger RNA (mRNA) levels in blood or saliva to help detect breast cancer or determine its prognosis. Owned by Mammogen with 53 claims and 1 forward citation, and it is expected to expire in 2042.
Coverage
What does this patent actually cover?
This patent outlines a method for detecting breast cancer or predicting its outcome. It involves measuring the levels of at least one specific type of molecule called messenger RNA (mRNA) in a sample from a person, like blood or saliva. These measured levels are then sent to a computer and compared to a baseline level from a healthy sample. If the mRNA levels are different, it can indicate the presence of breast cancer or help doctors understand how aggressive it might be. The patent lists 26 specific mRNAs that can be used, and suggests using a combination of them to create a 'biomarker fingerprint' for more accurate diagnosis or prognosis. It also mentions using this information to guide treatment decisions and distinguish between different stages of the cancer.
The gap
What does this patent NOT cover?
- Detecting breast cancer using only imaging techniques like mammograms.
- Diagnosing breast cancer based on physical examination alone.
- Using protein levels or DNA mutations as the primary diagnostic markers.
- Methods that do not involve measuring mRNA expression levels.
- Detecting cancers other than breast cancer.
These exclusions are unique to PatentBrief — derived from the actual claim language, not patent-office boilerplate.
Key facts
What made this novel
The innovation lies in identifying and utilizing a specific panel of 26 mRNA molecules whose expression levels in blood or saliva are significantly altered in the presence of breast cancer, creating a unique 'fingerprint' for diagnosis and prognosis.
Schematic visualization of the patent's claim structure. Hand-drawn diagrams in progress for each landmark patent.
Where you've seen this
Real-world examples
Mammogen Inc.'s diagnostic tests
Blood-based cancer screening technologies
Saliva-based diagnostic assays
Why it matters
The bigger picture
Early and accurate detection of breast cancer significantly improves treatment outcomes and patient survival rates. This patent offers a potential non-invasive method, using readily available samples like blood or saliva, to identify the disease or its likely progression. This could lead to earlier intervention and more personalized treatment strategies.
Filed
February 11, 2022
Market context
Who's building on this
Companies in this space
Mammogen Inc., the assigneeassigneeThe entity that owns the patent — usually the inventor's employer or a company.Read more →, is actively developing and commercializing this technology. Other companies in the diagnostics space are also exploring mRNA-based biomarkers for various cancers, though specific adoption of this exact panel would require further market analysis.
Market impact
This patent aims to establish a new standard for non-invasive breast cancer detection and prognosis. If successful, it could shift diagnostic paradigms away from solely relying on imaging and biopsies towards molecular profiling of blood or saliva, potentially improving accessibility and reducing patient discomfort.
Claim 1 — Plain English
What this patent covers
This patent outlines a method for detecting breast cancer or predicting its outcome. It involves measuring the levels of at least one specific type of molecule called messenger RNA (mRNA) in a sample from a person, like blood or saliva. These measured levels are then sent to a computer and compared to a baseline level from a healthy sample. If the mRNA levels are different, it can indicate the presence of breast cancer or help doctors understand how aggressive it might be. The patent lists 26 specific mRNAs that can be used, and suggests using a combination of them to create a 'biomarker fingerprint' for more accurate diagnosis or prognosis. It also mentions using this information to guide treatment decisions and distinguish between different stages of the cancer.
The clever bit
The innovation lies in identifying and utilizing a specific panel of 26 mRNA molecules whose expression levels in blood or saliva are significantly altered in the presence of breast cancer, creating a unique 'fingerprint' for diagnosis and prognosis.
What it does not cover
- Detecting breast cancer using only imaging techniques like mammograms.
- Diagnosing breast cancer based on physical examination alone.
- Using protein levels or DNA mutations as the primary diagnostic markers.
- Methods that do not involve measuring mRNA expression levels.
- Detecting cancers other than breast cancer.
Patent timeline
Application submitted to the patent office
Patent enters public domain
PatentBrief Score
Impact Score
Moderate
Citation count
6/40
Early citations
Claim breadth
20/20
Very broad protection
Recency
0/20
Older than 20 years
Assignee scale
20/20
Major company or institution
PatentBrief Impact Score — based on citation count, claim breadth, recency, and assignee scale. Not a legal assessment.
Heuristic Value Estimate
What this patent might be worth
$144K – $461K
Midpoint $288K · 15.2 yr remaining · industry ×3.0
Heuristic only — blends forward/backward citation counts, claim scope, time remaining, litigation history, and CPC-derived industry baseline. Real valuations need a professional appraisal.
Claim text not yet imported for this patent
The original legal language
Original claims
53 claims as filed with the patent office.
Concepts involved
Citations
Patent lineage
Cite this patent
Lilley, P., & III, M. J. K. Using Blood and Saliva mRNA to Detect Breast Cancer (U.S. Patent No. 20,240,117,444). U.S. Patent and Trademark Office. https://patentbrief.org/patent/us/20240117444/biomarkers-for-the-diagnosis-of-breast-cancer
Auto-generated from the patent record. Double-check author order and the issue date against the official USPTO document before submitting.
Embed
Add this patent to your site
Drop this plain-English patent card into any blog post or article — free, no signup. It always links back to the full breakdown here.
<div data-patentlens-widget data-patent-number="US20240117444"></div> <script src="https://patentbrief.org/embed.js" async></script>
Stay in the loop
Get a weekly digest of new patents.
One email per week. No spam. Unsubscribe anytime.
Keep exploring
Related patents you should know
US 4683195 · 1987
How to Make Billions of Copies of a DNA Segment
This patent describes the Polymerase Chain Reaction (PCR), a method to rapidly create many copies of a specific piece of DNA or RNA, enabling its detection and analysis.
Cetus Corp
US 8697359 · 2014
How to Edit Genes in Human Cells Using an Engineered CRISPR System
This patent describes an engineered CRISPR-Cas9 system for precisely cutting DNA in eukaryotic cells to change how genes work, opening the door for gene editing in complex organisms.
Massachusetts Institute of Technology
US 7657849 · 2010
How the iPhone's Slide-to-Unlock Gesture Works
Apple's 2010 patent describes unlocking a device by dragging a specific graphical image across the touchscreen along a predefined path, a gesture that became iconic with the original iPhone.
Apple Inc
US 4733665 · 1988
How Doctors Implant a Permanent Stent Using a Balloon
This patent describes the method for placing a permanent, expandable wire mesh tube inside a blood vessel or other body tube using a balloon-tipped catheter to widen it and keep it open.
Expandable Grafts Partnership
US 4965188 · 1990
How to Make Many Copies of a DNA Piece with Heat
This patent describes the Polymerase Chain Reaction (PCR) method, a technique to make millions of copies of a specific DNA segment using a heat-resistant enzyme and repeated temperature changes.
Cetus Corp
US 4235871 · 1980
How to Encapsulate Active Materials in Lipid Bubbles Efficiently
This patent describes a method for trapping biologically active substances inside tiny, multi-layered fat bubbles called liposomes, using a specific water-in-oil emulsion and gel-forming process to improve how much material gets captured.
Individual
Semantically similar
You might also find these interesting
US 8053198 · 2011 · Meso Scale Technologies
Method for Diagnosing Ovarian Cancer Using Biomarkers
US 20230274838 · OTRACES
How to Diagnose Cancer Better Using Multiple Blood Markers and Patient Data
US 10914745 · 2021 · Randox Laboratories
Using Blood Markers to Diagnose Stroke and Tell Its Type
US 12735751 · 2026
Finding Rare Genetic Changes in Blood Using DNA Fragments
More to explore
More in Biotech & Medicine
US 4683195 · 1987 · Cetus Corp
How to Make Billions of Copies of a DNA Segment
US 8697359 · 2014 · Massachusetts Institute of Technology
How to Edit Genes in Human Cells Using an Engineered CRISPR System
US 4733665 · 1988 · Expandable Grafts Partnership
How Doctors Implant a Permanent Stent Using a Balloon
US 4965188 · 1990 · Cetus Corp
How to Make Many Copies of a DNA Piece with Heat
New to patents?
Common Questions
Frequently Asked Questions
What does Using Blood and Saliva mRNA to Detect Breast Cancer cover?
This patent describes a method using specific messenger RNA (mRNA) levels in blood or saliva to help detect breast cancer or determine its prognosis.
Who owns patent US 20240117444?
This patent is owned by Mammogen.
When does this patent expire?
This patent is expected to expire on February 11, 2042, when the invention enters the public domain.
What is patent US 20240117444 cited by?
This patent has been cited by 1 later patents that build on its ideas.
What problem does this patent solve?
Early and accurate detection of breast cancer significantly improves treatment outcomes and patient survival rates. This patent offers a potential non-invasive method, using readily available samples like blood or saliva, to identify the disease or its likely progression. This could lead to earlier intervention and more personalized treatment strategies.
What does this patent NOT cover?
Detecting breast cancer using only imaging techniques like mammograms.
Patent monitoring





